http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112198317-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe10eac3ba729357cb556844914fe61e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0362 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-66 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58356c11266b1f84d2a9fc3dbfcf6d25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33e1dd566a7db13b311af8fe79bf64f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a445c4df53883d5c5312af6e95a5f227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb6d54a7950a322eec685fe0d7316e9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_811b12a5bf093ff87f5a5624cc3e7579 |
| publicationDate | 2021-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112198317-A |
| titleOfInvention | Method for evaluating and screening anti-diabetic osteoporosis medicine |
| abstract | The invention relates to a method for evaluating and screening an anti-diabetic osteoporosis drug, which comprises the following steps: 1) the zebra fish model group, the zebra fish treatment group and the zebra fish normal group are prepared; the three groups are replaced with corresponding culture aqueous solution every 1 day; 2) observing the shapes and the lengths of the normal group, the model group and the treatment group of the zebra fish prepared in the step (1); 3) observing skull skeletons of the normal group, the model group and the treatment group of the zebra fish by an alizarin red staining method, and 4) detecting the expression levels of blood sugar, high-density lipoprotein and triglyceride of the normal group, the model group and the treatment group of the zebra fish by an enzyme-linked immunosorbent assay. The established zebra fish diabetic osteoporosis model has the advantages of simple and rapid manufacture, stability, reliability and good repeatability, the dosage of the medicine is small when the model is used for evaluating the medicine efficacy, the manufacture cost of the diabetic osteoporosis model and the related medicine efficacy evaluation cost are reduced, and the reliability and the evaluation efficiency of the experimental result are improved. |
| priorityDate | 2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.